• Fri. Aug 12th, 2022

LexaGene Announces Advancements for its Sample Prep Cartridge for the Veterinary Market

ByRandall B. Phelps

Mar 29, 2022

Content of the article

BEVERLY, Mass., March 29, 2022 (GLOBE NEWSWIRE) — LexaGene Holdings Inc.(TSX-V:LXG; OTCQB: LXXGF) (the “Company”), a molecular diagnostics company that commercialized the MiQLab® Systema fully automated rapid pathogen test device, today announced enhancements to its sample prep cartridge for processing complex samples.

LexaGene’s MiQLab® System is designed to process liquid companion animal samples used in the diagnosis of infections such as urinary tract infections (UTIs) and skin infections. The system, equipped with a MiQLab® Bacteria and AMR Panel, analyzing samples for 10 common pathogens and 33 markers for antimicrobial resistance (AMR) testing. These antimicrobial resistance tests target genes that confer resistance to four classes of first-line treatments, namely tetracyclines, beta-lactams, sulfa-TMPs and lincosamides.

Advertisement 2

Content of the article

Dr. Jack Regan, CEO and Founder of LexaGene, said, “Some sample types are easily processed for PCR testing, such as nasal swab samples, while other sample types contain inhibitors that interfere with PCR. To better handle more complex samples, we have recently incorporated new chemistry into our sample prep cartridge that greatly improves the ability of the MiQLab system to process samples containing a large percentage of blood, which is a strong PCR inhibitor. . We are excited about this advancement and believe the new sample prep cartridge expands our pet testing capabilities.

To learn more about LexaGene and the MiQLab System or subscribe to company updatesto visit www.lexagene.comor follow us on Twitter Where LinkedIn.

Advertisement 3

Content of the article

About LexaGene Holdings Inc.
LexaGene is a molecular diagnostics company that develops molecular diagnostic systems for the detection of pathogens and genetic testing for other molecular markers for rapid on-site testing in veterinary diagnostics, food safety and for use on open access markets such as clinical research, agricultural testing and biodefense. End users simply take a sample, load it onto the instrument with a sample prep cartridge, enter the sample ID, and press “go”. The MiQLab® system offers excellent sensitivity, specificity and detection range and can return results in approximately two hours. The unique open-access feature is designed for custom testing so end users can load their own real-time PCR assays onto the instrument to target any genetic target of interest.

Advertisement 4

Content of the article

The TSX Venture Exchange Inc. has in no way passed on the merits of the proposed transaction and has neither approved nor disapproved of the contents of this press release. Neither the TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.

This press release contains forward-looking information, which involves known and unknown risks, uncertainties and other factors that may cause actual events to differ materially from current expectations. Important factors – including availability of funds, results of fundraising efforts, success of technology development efforts, cost of purchasing critical parts, instrument performance, technology acceptance by the market, regulatory acceptance and licensing issues – which could cause actual results to differ materially from the Company’s expectations as disclosed in the Company’s documents filed from time to time on SEDAR (see www.sedar.com). Readers are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date of this press release. The Company disclaims any intention or obligation, except to the extent required by law, to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise.



Postmedia is committed to maintaining a lively yet civil discussion forum and encourages all readers to share their views on our articles. Comments can take up to an hour to be moderated before appearing on the site. We ask that you keep your comments relevant and respectful. We have enabled email notifications. You will now receive an email if you receive a reply to your comment, if there is an update to a comment thread you follow, or if a user follows you comments. Visit our Community Rules for more information and details on how to adjust your E-mail settings.